Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EDUFLUVAC

Financiado

Cerrado

Combinatorial immunization strategy to educate the immune system towards cross r...

Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure As current influenza vaccines only afford limited protection against seasonal as well as pandemic influenza, and require regular updating, the development of a universal influenza vaccine that can provide broad coverage against di... ver más

31/10/2017

EUROPEAN VACCINE I...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

EUROPEAN VACCINE INITIATIVE EWIV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-10-31 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

EUROPEAN VACCINE INITIATIVE

0.00€ | Lider

BPRC

N.D. | Participante

ETNA

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FLUNIVAC InFLUenza virus UNIVersal VACcine development program 7M€ Cerrado

IMECS Identification of Mechanisms Correlating with Susceptibility... 4M€ Cerrado

UNIFLUVAC A novel universal influenza vaccine targeting epitopes of li... 149K€ Cerrado

FLU-MAL VLP Chimeric Influenza VLP used as vaccine platform for presenta... 194K€ Cerrado

B-DOMINANCE B Cell Immunodominance in Antiviral Immunity 1M€ Cerrado

MAJARVISCIG A Single Dose Cytomegalovirus based Vaccine to Induce Heter... 100K€ Cerrado

Líder del proyecto

EUROPEAN VACCINE INITIATIVE EWIV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto As current influenza vaccines only afford limited protection against seasonal as well as pandemic influenza, and require regular updating, the development of a universal influenza vaccine that can provide broad coverage against different strains within a subtype or even across subtypes has become a key health care priority in both industrialized and low and middle income countries. EDUFLUVAC aims to develop an influenza vaccine that educates the immune system to recognise common influenza epitopes, using a combination of influenza haemagglutinin (HA) antigens delivered on a single virus-like particle. This vaccine concept, using the proven, modern technology of baculovirus VLPs will enable enhanced cross linking of B-cell receptors and favour induction of B-cell responses against common epitopes essential for long-lasting cross recognition and protection. The mechanism underlying the broadening of antibody responses is the increased relative concentration of common epitopes diluting out strain specific epitopes. This will be achieved by testing the ability of a combination of historic HA variants to protect against a variety of modern isolates. A similar approach for developing a novel vaccine for pandemic use will be tested. The knowledge generated will provide Proof of Principle in relevant animal models for an influenza vaccine that does not have to be updated annually, does not have to be manufactured on an annual basis and will not require an annual vaccination campaign. It will also provide for an economically viable large scale production platform for influenza vaccine which, in the event of a pandemic, can manufacture rapidly high quantities of vaccine. All industrial partners (including two SMEs) will benefit from the compilation of the regulatory dossier for transfer to larger vaccine companies and the deeper knowledge integration emanating from EDUFLUVAC in a $2.8 billion global annual influenza vaccine market.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores